Bruker Co. (NASDAQ:BRKR) Receives $70.50 Average Target Price from Brokerages

Bruker Co. (NASDAQ:BRKR) has earned an average rating of “Moderate Buy” from the eleven research firms that are presently covering the firm, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $70.50.

Several equities research analysts have recently weighed in on the stock. Bank of America upped their price target on shares of Bruker from $78.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday, December 13th. TD Cowen cut their price objective on shares of Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a research note on Wednesday, November 6th. UBS Group began coverage on Bruker in a research report on Tuesday, December 10th. They set a “neutral” rating and a $66.00 price target for the company. Citigroup decreased their price objective on shares of Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Finally, Wells Fargo & Company decreased their target price on Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 6th.

Institutional Trading of Bruker

Large investors have recently modified their holdings of the business. Sanctuary Advisors LLC purchased a new position in shares of Bruker during the 2nd quarter valued at approximately $296,000. Inspire Advisors LLC acquired a new position in Bruker during the 3rd quarter worth $226,000. Ferguson Wellman Capital Management Inc. increased its position in shares of Bruker by 16.5% in the 3rd quarter. Ferguson Wellman Capital Management Inc. now owns 16,041 shares of the medical research company’s stock worth $1,108,000 after purchasing an additional 2,270 shares during the last quarter. Allspring Global Investments Holdings LLC increased its position in shares of Bruker by 51.1% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 210,761 shares of the medical research company’s stock worth $14,555,000 after purchasing an additional 71,275 shares during the last quarter. Finally, Sequoia Financial Advisors LLC raised its stake in shares of Bruker by 3.8% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 34,172 shares of the medical research company’s stock valued at $2,360,000 after purchasing an additional 1,251 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Price Performance

Shares of BRKR stock opened at $52.92 on Friday. The stock has a 50 day moving average price of $56.87 and a 200 day moving average price of $60.13. The firm has a market capitalization of $8.02 billion, a P/E ratio of 69.63, a P/E/G ratio of 2.07 and a beta of 1.16. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60. Bruker has a 52-week low of $48.07 and a 52-week high of $94.86.

Bruker (NASDAQ:BRKR) last released its earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share for the quarter, topping the consensus estimate of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. As a group, sell-side analysts predict that Bruker will post 2.69 earnings per share for the current year.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.